| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | barasertib | CTRPv2 | pan-cancer | AAC | 0.35 | 5e-23 |
| mRNA | alisertib | CTRPv2 | pan-cancer | AAC | 0.3 | 1e-18 |
| mRNA | Cytarabine | CTRPv2 | pan-cancer | AAC | 0.26 | 2e-16 |
| mRNA | carboplatin:etoposide (40:17 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.27 | 1e-15 |
| mRNA | Mitomycin-C | CTRPv2 | pan-cancer | AAC | 0.29 | 1e-14 |
| mRNA | PX-12 | CTRPv2 | pan-cancer | AAC | 0.24 | 3e-14 |
| mRNA | ceranib-2 | CTRPv2 | pan-cancer | AAC | 0.27 | 1e-13 |
| mRNA | etoposide | CTRPv2 | pan-cancer | AAC | 0.25 | 2e-13 |
| mRNA | GSK1070916 | GDSC1000 | pan-cancer | AAC | 0.24 | 6e-13 |
| mRNA | Vorinostat | GDSC1000 | pan-cancer | AAC | 0.23 | 8e-13 |